Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of kidney transplant patients treated with imlifidase or plasma exchange after AMR
2020-004777-49Phase 2Completed
- Sponsor
- Hansa Biopharma
- Start
- Oct 2020
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of imlifidase in Antibody-mediated kidney allograft rejection (AMR) and kidney allograft rejection (2 arms), sponsored by Hansa Biopharma. Primary endpoint: Overall graft survival at Year 3. Started Oct 2020; status: completed.
02
Drugs
imlifidase
03
Conditions
Antibody-mediated kidney allograft rejection (AMR)kidney allograft rejection
Beyond the preview
Go deeper on 2020-004777-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004777-49.